Novo Nordisk Files Patent Suit To Stop Hims' Compounded Wegovy, Semaglutide Sales
- Posted on February 10, 2026
- By International Business Times
- 7 Views
Novo Nordisk Files Patent Suit To Stop Hims' Compounded Wegovy, Semaglutide Sales
The lawsuit comes after Hims & Hers briefly launched a $49 compounded version of Wegovy and abandoned the product following FDA warnings, triggering a sharp drop in Hims' stock and a rise in Novo Nordisk shares.
